Original language | English (US) |
---|---|
Pages (from-to) | 92-95 |
Number of pages | 4 |
Journal | Leukemia Research |
Volume | 72 |
DOIs | |
State | Published - Sep 2018 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Access to Document
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). / Zeidner, Joshua F.; Foster, Matthew C.; Blackford, Amanda L.; Litzow, Mark R.; Morris, Lawrence E.; Strickland, Stephen A.; Lancet, Jeffrey E.; Bose, Prithviraj; Levy, M. Yair; Tibes, Raoul; Gojo, Ivana; Gocke, Christopher D.; Rosner, Gary L.; Little, Richard F.; Wright, John J.; Doyle, L. Austin; Smith, B. Douglas; Karp, Judith E.
In: Leukemia Research, Vol. 72, 09.2018, p. 92-95.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)
AU - Zeidner, Joshua F.
AU - Foster, Matthew C.
AU - Blackford, Amanda L.
AU - Litzow, Mark R.
AU - Morris, Lawrence E.
AU - Strickland, Stephen A.
AU - Lancet, Jeffrey E.
AU - Bose, Prithviraj
AU - Levy, M. Yair
AU - Tibes, Raoul
AU - Gojo, Ivana
AU - Gocke, Christopher D.
AU - Rosner, Gary L.
AU - Little, Richard F.
AU - Wright, John J.
AU - Doyle, L. Austin
AU - Smith, B. Douglas
AU - Karp, Judith E.
N1 - Funding Information: This study was supported in part by NCI Cooperative Agreement U01 CA70095 and NCI Cancer Center Support Grant 2P30 CA06973-46. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/9
Y1 - 2018/9
UR - http://www.scopus.com/inward/record.url?scp=85051399141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051399141&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2018.08.005
DO - 10.1016/j.leukres.2018.08.005
M3 - Letter
C2 - 30118897
AN - SCOPUS:85051399141
VL - 72
SP - 92
EP - 95
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
ER -